EXENATIDE ( DrugBank: Exenatide )

6 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	10
17	多系統萎縮症	2
72	下垂体性ADH分泌異常症	1
78	下垂体前葉機能低下症	2
193	プラダー・ウィリ症候群	3
233	ウォルフラム症候群	1

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

diseases per page:

Showing 1 to 10 of 10 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04269642 (ClinicalTrials.gov)	March 19, 2020	13/1/2020	SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease	Phase IIa Study to Evaluate the Efficacy and Safety of Subcutaneous SR-Exenatide(PT320) in Patients ...	Early Parkinson's Disease	Drug: PT320 2.0mg Placebo;Drug: PT320 2.0 mg;Drug: PT320 2.5 mg	Peptron, Inc.	NULL	Active, not recruiting	40 Years	75 Years	All	99	Phase 2	Korea, Republic of
2	NCT04305002 (ClinicalTrials.gov)	January 21, 2020	20/2/2020	Exenatide Treatment in Parkinson's Disease	Effect of Exenatide on Disease Progression in Early Parkinson's Disease	Parkinson Disease	Drug: Exenatide;Drug: Placebo	Center for Neurology, Stockholm	Karolinska Institutet	Active, not recruiting	25 Years	80 Years	All	60	Phase 2	Sweden
3	NCT04232969 (ClinicalTrials.gov)	January 20, 2020	10/1/2020	ExenatideOnce Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease ...	A Randomised, Double Blind, Parallel Group, Placebo Controlled, Phase 3 Trial of ExenatideOnce Weekl ...	Parkinson's Disease	Drug: Exenatide extended release 2mg (Bydureon)	University College, London	NULL	Active, not recruiting	25 Years	80 Years	All	194	Phase 3	United Kingdom
4	EUCTR2019-000732-26-SE (EUCTR)	23/10/2019	07/05/2019	Exenatide Treatment in Parkinson's Disease	Effect of Exenatide on disease progression in early Parkinson's disease.	Parkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Bydureon 2 mg powder and solvent for prolonged-release suspension Product Name: BYDUREON I ...	Stockholm Health Care Services	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 2	Sweden
5	EUCTR2018-003028-35-GB (EUCTR)	04/09/2019	15/11/2019	A randomised, double blind, parallel group, placebo controlled, Phase 3 trial of exenatideonce weekl ...	A randomised, double blind, parallel group, placebo controlled, Phase 3 trial of exenatideonce weekl ...	Parkinson's disease MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parki ...	Trade Name: Bydureon Product Name: Bydureon INN or Proposed INN: Exenatide	University College London Comprehensive Clinical Trial Unit	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	200	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	United Kingdom
6	NCT03456687 (ClinicalTrials.gov)	June 5, 2018	1/3/2018	Effects of Exenatide on Motor Function and the Brain	Effects of Exenatide on Motor Function and the Brain	Parkinson's Disease	Drug: Exenatide	University of Florida	National Institute of Neurological Disorders and Stroke (NINDS)	Completed	40 Years	77 Years	All	5	Phase 1	United States
7	NCT01971242 (ClinicalTrials.gov)	June 2014	23/10/2013	Trial of Exenatide for Parkinson's Disease	A Randomised, Double Blind, Placebo Controlled, Single Centre, 60 Week Trial of ExenatideOnce Weekly ...	Parkinson's Disease	Drug: Exenatide;Other: Placebo	University College, London	NULL	Completed	25 Years	75 Years	Both	60	Phase 2	United Kingdom
8	EUCTR2013-003363-64-GB (EUCTR)	03/04/2014	11/03/2014	Trial of Exenatide for Parkinson's disease	A randomised, double blind, placebo controlled, single centre, 60 week trial of Exenatideonce weekly ...	Parkinson's Disease MedDRA version: 16.1;Level: LLT;Classification code 10013113;Term: Disease Parki ...	Trade Name: Bydureon Product Name: Exenatide INN or Proposed INN: exenatide	University College London	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2	United Kingdom
9	NCT01174810 (ClinicalTrials.gov)	July 2010	2/8/2010	Exendin-4 as a Treatment for Parkinson's Disease - Pilot Study	An Open Label, Single Site, 12 Month, Phase II, Randomised Controlled Trial Evaluating the Safety an ...	Parkinson's Disease	Drug: Exenatide	University College, London	NULL	Active, not recruiting	45 Years	70 Years	Both	40	Phase 2	United Kingdom
10	EUCTR2009-018137-37-GB (EUCTR)	14/04/2010	18/03/2010	An open label, single site, 12 month, Phase II, randomised controlled trial evaluating the safety an ...	An open label, single site, 12 month, Phase II, randomised controlled trial evaluating the safety an ...	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's di ...	Trade Name: Byetta 5 micrograms Product Name: Exenatide5 micrograms Trade Name: Exenatide10 micrograms ...	University College London	NULL	Not Recruiting			Female: yes Male: yes	40	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	United Kingdom

First Previous1Next Last

先頭へ

17. 多系統萎縮症

臨床試験数 : 119 / 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04431713 (ClinicalTrials.gov)	September 16, 2020	29/5/2020	Exenatide Once-weekly as a Treatment for Multiple System Atrophy	An Open Label, Single Site, 48 Week, Randomised Controlled Trial Evaluating the Safety and Efficacy ...	Multiple System Atrophy	Drug: Exenatide Pen Injector [Bydureon]	University College, London	NULL	Recruiting	30 Years	80 Years	All	50	Phase 2	United Kingdom
2	EUCTR2020-000122-26-GB (EUCTR)	11/05/2020	06/04/2020	Exenatide once-weekly as a treatment for Multiple System Atrophy.	A Phase IIa, open label, single-site, 48 week randomised controlled trial evaluating the safety and ...	Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple s ...	Trade Name: Bydureon Product Name: Bydureon INN or Proposed INN: Exenatide	University College London (UCL)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50	Phase 2	United Kingdom

First Previous1Next Last

72. 下垂体性ADH分泌異常症

臨床試験数 : 41 / 薬物数 : 27 - (DrugBank : 8) / 標的遺伝子数 : 7 - 標的パスウェイ数 : 10

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04897802 (ClinicalTrials.gov)	September 13, 2021	17/5/2021	Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)	Identification and Clinical Relevance of an Oxytocin Deficient State: a Randomized, Crossover, Place ...	Hypopituitarism;Central Diabetes Insipidus;Panhypopituitarism;Psychological Disorder;Social Isolatio ...	Drug: Experimental: GLP1-RA (exenatide) administration;Drug: Control: Placebo administration	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	Instituto de Salud Carlos III	Recruiting	18 Years	65 Years	All	52	Phase 4	Spain

First Previous1Next Last

78. 下垂体前葉機能低下症

臨床試験数 : 492 / 薬物数 : 341 - (DrugBank : 47) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 100

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04897802 (ClinicalTrials.gov)	September 13, 2021	17/5/2021	Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)	Identification and Clinical Relevance of an Oxytocin Deficient State: a Randomized, Crossover, Place ...	Hypopituitarism;Central Diabetes Insipidus;Panhypopituitarism;Psychological Disorder;Social Isolatio ...	Drug: Experimental: GLP1-RA (exenatide) administration;Drug: Control: Placebo administration	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	Instituto de Salud Carlos III	Recruiting	18 Years	65 Years	All	52	Phase 4	Spain
2	EUCTR2020-004115-27-ES (EUCTR)	10/05/2021	01/09/2021	Identification and clinical relevance of oxytocin deficient status: GLP1 study	Identification and clinical relevance of oxytocin deficient status: randomized, crossover, placebo-c ...	Hypopituitarism;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Trade Name: Byetta INN or Proposed INN: EXENATIDE	Institut de Recerca Hospital de la Santa Creu i Sant Pau - IIB Sant Pau	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	52	Phase 2	Spain

First Previous1Next Last

193. プラダー・ウィリ症候群

臨床試験数 : 113 / 薬物数 : 111 - (DrugBank : 26) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 102

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01444898 (ClinicalTrials.gov)	March 2012	27/9/2011	Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome	Effects of Exenatide on Obesity and Appetite in Overweight Patients With Prader-Willi Syndrome	Prader-Willi Syndrome	Drug: Exenatide	Children's Hospital Los Angeles	NULL	Completed	13 Years	20 Years	All	10	N/A	United States
2	EUCTR2010-023179-25-GB (EUCTR)	13/09/2011	27/07/2011	Effects of exenatideon appetite and ghrelin levels in patients with Prader-Willi Syndrome - Effects ...	Effects of exenatideon appetite and ghrelin levels in patients with Prader-Willi Syndrome - Effects ...	Ghrelin levels in patients with Prader Willi Syndrome and healthy controls and response of ghrelin l ...	Trade Name: Byetta Product Name: Byetta Product Code: EU/1/06/362/003: 5µg (1 pen) INN or Proposed INN: ...	Aintree University Hospital NHS Foundation Trust	UNIVERSITY OF LIVERPOOL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			United Kingdom
3	NCT00551343 (ClinicalTrials.gov)	October 2007	29/10/2007	Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome	Contribution of a GLP-1 Agonist to Appetite Regulation, Metabolism and Body Composition in Subjects ...	Prader-Willi Syndrome	Drug: Exenatide	Garvan Institute of Medical Research	NULL	Completed	18 Years	45 Years	All	20	N/A	Australia

First Previous1Next Last

233. ウォルフラム症候群

臨床試験数 : 11 / 薬物数 : 17 - (DrugBank : 8) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 41

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01302327 (ClinicalTrials.gov)	March 2011	22/2/2011	GLP Analogs for Diabetes in Wolfram Syndrome Patients		Diabetes Mellitus Associated With Genetic Syndrome;Wolfram Syndrome	Drug: Exenatide	Hadassah Medical Organization	NULL	Not yet recruiting	18 Years	N/A	Both	10	N/A	NULL

First Previous1Next Last

先頭へ